Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
Can-Fite submitted a Phase 2 clinical study protocol to Bambino Gesù Children's Hospital for Piclidenoson targeting Lowe syndrome, a rare genetic disorder with no approved therapies. The open-label pilot study will enroll five adult patients for six months of twice-daily oral dosing, focusing on renal uptake as the primary endpoint.
Key figures
- Drug Name
- Piclidenoson
- Phase Of Trial
- Phase 2
- Patient count
- 5
- Duration months
- 6
- Dosing frequency
- twice daily
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.